ATH-63 / Athos Therap - LARVOL DELTA

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Athos Therapeutics Inc | Recruiting ➔ Completed

Trial completion • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects (clinicaltrials.gov) - P1 | N=76 | Not yet recruiting | Sponsor: Athos Therapeutics Inc

New P1 trial • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATH-063 in Healthy Subjects (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: Athos Therapeutics Inc | Not yet recruiting ➔ Recruiting

Enrollment open • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063 (PRNewswire) - "Athos Therapeutics...announced today that it has been granted a CTN acknowledgement from the Australian Therapeutic Goods Administration and has received Human Research Ethics Committee ('HREC') approval to commence a Phase I clinical trial of ATH-063 in Australia....'The TGA's acknowledgement of our application to initiate clinical evaluation of ATH-063 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with Inflammatory Bowel Disease,' said Dimitrios Iliopoulos, PhD, MBA, President & CEO, CEO of Athos."

New P1 trial • Immunology • Inflammatory Bowel Disease

Athos Therapeutics Announces the Completion of its Oversubscribed Series A Financing (PRNewswire) - "Athos Therapeutics, Inc...announced today the completion of an oversubscribed $15MM Series A financing. The funding will be used to advance the company's pre-clinical and clinical programs, including the initiation of a first in human phase I clinical trial of ATH-63 in 2022. Athos is developing ATH-63 for Inflammatory Bowel Disease, Lupus, other autoimmune disorders, and select cancer indications."

Financing • New P1 trial • Inflammatory Bowel Disease